Subtopic Deep Dive

Breast MRI Neoadjuvant Chemotherapy Response
Research Guide

What is Breast MRI Neoadjuvant Chemotherapy Response?

Breast MRI Neoadjuvant Chemotherapy Response uses dynamic contrast-enhanced MRI (DCE-MRI) and other sequences to predict pathological complete response (pCR) to neoadjuvant chemotherapy (NAC) in breast cancer by assessing tumor volume changes and functional metrics.

Researchers apply multiparametric MRI including radiomics, texture analysis, and amide proton transfer (APT) imaging to evaluate NAC response early. Systematic reviews confirm MRI's role in predicting pCR with moderate accuracy across studies. Over 10 key papers since 2010, led by Braman et al. (2017, 619 citations) and Marinovich et al. (2012, 195 citations), establish quantitative imaging biomarkers.

15
Curated Papers
3
Key Challenges

Why It Matters

Breast MRI guides therapy adjustments during NAC, enabling switches to alternative regimens for non-responders and improving survival in HER2-positive cases (Bitencourt et al., 2020). Radiomics from DCE-MRI predicts pCR pre-treatment, reducing overtreatment (Braman et al., 2017). Longitudinal models fuse MRI data across cycles for multicenter validation, enhancing clinical decision-making (Huang et al., 2023). Functional metrics like ADC identify responders early, correlating with pathologic outcomes (Fangberget et al., 2010).

Key Research Challenges

Radiomic Feature Reproducibility

Inter-site variability in DCE-MRI radiomics limits generalizability for pCR prediction (Braman et al., 2017). Standardization of imaging protocols remains inconsistent across centers. Validation on diverse cohorts is needed (Marinovich et al., 2012).

Early Response Prediction Accuracy

MRI sensitivity for early NAC response varies, with systematic reviews showing pooled accuracy below 80% (Marinovich et al., 2012). Distinguishing viable tumor from necrosis challenges volume-based metrics. Multiparametric fusion improves but requires larger trials (Wu et al., 2016).

Integration of Molecular Subtypes

Predicting response in HER2-overexpressing cancers demands subtype-specific radiomics (Bitencourt et al., 2020). APT imaging reproducibility for chemotherapy assessment needs multicenter confirmation (Dula et al., 2012). Longitudinal models face data scarcity in rare subtypes (Huang et al., 2023).

Essential Papers

1.

Intratumoral and peritumoral radiomics for the pretreatment prediction of pathological complete response to neoadjuvant chemotherapy based on breast DCE-MRI

Nathaniel Braman, Maryam Etesami, Prateek Prasanna et al. · 2017 · Breast Cancer Research · 619 citations

2.

Early prediction of pathologic response to neoadjuvant therapy in breast cancer: Systematic review of the accuracy of MRI

M. Luke Marinovich, Francesco Sardanelli, Stefano Ciatto et al. · 2012 · The Breast · 195 citations

Magnetic resonance imaging (MRI) has been proposed to have a role in predicting final pathologic response when undertaken early during neoadjuvant chemotherapy (NAC) in breast cancer. This paper ex...

3.

Magnetic resonance imaging in breast cancer: A literature review and future perspectives

Gisela L. G. Menezes · 2014 · World Journal of Clinical Oncology · 179 citations

Early detection and diagnosis of breast cancer are essential for successful treatment. Currently mammography and ultrasound are the basic imaging techniques for the detection and localization of br...

4.

Intratumor partitioning and texture analysis of dynamic contrast‐enhanced (DCE)‐MRI identifies relevant tumor subregions to predict pathological response of breast cancer to neoadjuvant chemotherapy

Jia Wu, G. Gong, Yi Cui et al. · 2016 · Journal of Magnetic Resonance Imaging · 166 citations

Purpose To predict pathological response of breast cancer to neoadjuvant chemotherapy (NAC) based on quantitative, multiregion analysis of dynamic contrast enhancement magnetic resonance imaging (D...

5.

Amide proton transfer imaging of the breast at 3 T: Establishing reproducibility and possible feasibility assessing chemotherapy response

Adrienne N. Dula, Lori R. Arlinghaus, Richard Dortch et al. · 2012 · Magnetic Resonance in Medicine · 166 citations

Abstract Chemical exchange saturation transfer imaging can generate contrast that is sensitive to amide protons associated with proteins and peptides (termed amide proton transfer, APT). In breast ...

6.

MRI-based machine learning radiomics can predict HER2 expression level and pathologic response after neoadjuvant therapy in HER2 overexpressing breast cancer

Almir Galvão Vieira Bitencourt, Peter Gibbs, Carolina Rossi Saccarelli et al. · 2020 · EBioMedicine · 156 citations

NIH/NCI (P30CA008748), Susan G. Komen Foundation, Breast Cancer Research Foundation, Spanish Foundation Alfonso Martin Escudero, European School of Radiology.

7.

Neoadjuvant chemotherapy in breast cancer-response evaluation and prediction of response to treatment using dynamic contrast-enhanced and diffusion-weighted MR imaging

Anne Fangberget, Line Brennhaug Nilsen, Knut Håkon Hole et al. · 2010 · European Radiology · 145 citations

ADC, tumour size and tumour size reduction at Tp1 were strong independent predictors of pCR.

Reading Guide

Foundational Papers

Start with Marinovich et al. (2012) systematic review for MRI accuracy evidence, then Fangberget et al. (2010) on ADC predictors of pCR, followed by Dula et al. (2012) for APT feasibility.

Recent Advances

Study Braman et al. (2017) radiomics benchmark, Bitencourt et al. (2020) HER2 radiomics, and Huang et al. (2023) longitudinal fusion for latest multicenter advances.

Core Methods

Core techniques: DCE-MRI radiomics and texture analysis (Braman 2017; Wu 2016), diffusion-weighted ADC (Fangberget 2010), APT chemical exchange saturation transfer (Dula 2012), machine learning classifiers (Bitencourt 2020).

How PapersFlow Helps You Research Breast MRI Neoadjuvant Chemotherapy Response

Discover & Search

Research Agent uses searchPapers and exaSearch to retrieve top-cited works like Braman et al. (2017) on intratumoral radiomics for pCR prediction, then citationGraph maps forward citations to Huang et al. (2023) longitudinal models and findSimilarPapers uncovers related APT studies by Dula et al. (2012).

Analyze & Verify

Analysis Agent applies readPaperContent to extract radiomic features from Braman et al. (2017), verifies pCR prediction claims via verifyResponse (CoVe) against Marinovich et al. (2012) meta-analysis, and runs PythonAnalysis with NumPy/pandas to reanalyze reported AUCs, graded by GRADE for evidence quality in NAC response studies.

Synthesize & Write

Synthesis Agent detects gaps in early pCR prediction via contradiction flagging between texture analysis papers (Wu et al., 2016; Teruel et al., 2014), while Writing Agent uses latexEditText for manuscript sections, latexSyncCitations for 10+ references, and latexCompile for figures; exportMermaid visualizes radiomics workflow diagrams.

Use Cases

"Reproduce radiomics AUC for pCR prediction from Braman 2017 DCE-MRI data."

Research Agent → searchPapers('Braman radiomics') → Analysis Agent → readPaperContent → runPythonAnalysis (NumPy/pandas ROC curve recompute) → researcher gets verified AUC plot and GRADE score.

"Write LaTeX review on MRI NAC response predictors."

Synthesis Agent → gap detection → Writing Agent → latexEditText('MRI NAC review') → latexSyncCitations(10 papers) → latexCompile → researcher gets compiled PDF with synced Braman/Marinovich citations.

"Find code for breast MRI texture analysis in NAC papers."

Research Agent → paperExtractUrls → Code Discovery → paperFindGithubRepo → githubRepoInspect → researcher gets GitHub repos with DCE-MRI radiomics pipelines linked to Wu et al. (2016).

Automated Workflows

Deep Research workflow conducts systematic review: searchPapers(50+ NAC MRI papers) → citationGraph → DeepScan(7-step: readPaperContent, verifyResponse, runPythonAnalysis on ADC metrics) → structured report on pCR predictors. Theorizer generates hypotheses like 'APT + radiomics fusion outperforms DCE alone' from Dula (2012) and Braman (2017). DeepScan verifies meta-analysis claims from Marinovich (2012) with CoVe checkpoints.

Frequently Asked Questions

What defines Breast MRI Neoadjuvant Chemotherapy Response?

It involves DCE-MRI radiomics and functional imaging to predict pCR to NAC by quantifying tumor changes pre- and mid-treatment (Braman et al., 2017).

What are key methods in this subtopic?

Methods include intratumoral radiomics (Braman et al., 2017), multiregion texture analysis (Wu et al., 2016), APT imaging (Dula et al., 2012), and longitudinal fusion models (Huang et al., 2023).

What are the most cited papers?

Braman et al. (2017, 619 citations) on radiomics; Marinovich et al. (2012, 195 citations) systematic review; Wu et al. (2016, 166 citations) on DCE-MRI subregions.

What are open problems?

Challenges include radiomic reproducibility across sites, improving early prediction accuracy beyond 80%, and subtype-specific models for HER2 cancers (Bitencourt et al., 2020; Marinovich et al., 2012).

Research MRI in cancer diagnosis with AI

PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:

See how researchers in Health & Medicine use PapersFlow

Field-specific workflows, example queries, and use cases.

Health & Medicine Guide

Start Researching Breast MRI Neoadjuvant Chemotherapy Response with AI

Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.

See how PapersFlow works for Medicine researchers